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Abstract 
Over the last 15 years, the majority of malaria drug discovery and development efforts have focused on new mol-
ecules and regimens to treat patients with uncomplicated or severe disease. In addition, a number of new molecular 
scaffolds have been discovered which block the replication of the parasite in the liver, offering the possibility of new 
tools for oral prophylaxis or chemoprotection, potentially with once-weekly dosing. However, an intervention which 
requires less frequent administration than this would be a key tool for the control and elimination of malaria. Recent 
progress in HIV drug discovery has shown that small molecules can be formulated for injections as native molecules 
or pro-drugs which provide protection for at least 2 months. Advances in antibody engineering offer an alternative 
approach whereby a single injection could potentially provide protection for several months. Building on earlier 
profiles for uncomplicated and severe malaria, a target product profile is proposed here for an injectable medicine 
providing long-term protection from this disease. As with all of such profiles, factors such as efficacy, cost, safety and 
tolerability are key, but with the changing disease landscape in Africa, new clinical and regulatory approaches are 
required to develop prophylactic/chemoprotective medicines. An overall framework for these approaches is sug-
gested here.
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Introduction
One of the challenges of malaria control is to be able 
to provide protection for vulnerable populations. In 
recent years, there has been great progress in the use of 
drug regimens to prevent infections in children. How-
ever, these require frequent drug administration. One 
alternative that has been tested is the use of long-acting 
injectable formulations. Although there are currently 
no long-acting injectable medicines in development for 
malaria, new formulation technologies, similar to those 
developed for prophylaxis against HIV, might point the 
way to new approaches against this disease. In addition, 
recent developments in monoclonal antibody technology 
may be applicable to protect against malaria, especially 
in vulnerable populations. This paper discusses how 
such treatments would fit the target product profiles for 
malaria, and a regulatory pathway for their development. 
Since they pose similar challenges and possibilities from 
this perspective, the discussion of small molecules and 
antibodies was combined.
Background
Over the last decade, there has been a consider-
able increase in the portfolio of new molecules which 
are being developed for the treatment of malaria [1, 
2]. New paradigms of screening [3–8] have led to 
another generation of molecules progressing to clinical 
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development, aimed at producing new medicines which 
overcome the current problems of multi-drug resist-
ant malaria [9–11] and which also simplify therapy 
from the current 3-day therapy, to single exposure 
cures. Protecting vulnerable populations from clinically 
significant infections is also a key aspect of malaria 
control and elimination [12]. Although a highly effec-
tive vaccine is the ultimate goal of much basic malaria 
research, the absence of a sterilizing immune response 
to naturally acquired disease shows how difficult such 
a target is likely to be [13]; current candidate vaccines 
provide a protective efficacy in the range of 30–50% 
[14].
Malaria chemoprophylaxis can be achieved by a vari-
ety of different mechanisms. Causal prophylactics tar-
get the asexual hepatic stages of malaria. Atovaquone (a 
Plasmodium mitochondrial  bc1 inhibitor binding to the 
 Q0 site of the complex), pyrimethamine and cycloguanil 
and its prodrug proguanil (selective inhibitors of dihy-
drofolate reductase, DHFR), sulfadoxine (an inhibitor of 
Plasmodium dihydropteroate synthase, DHPS) and the 
8-aminoquinolines primaquine and tafenoquine are the 
only causal prophylactics with proven clinical efficacy. In 
suppressive chemoprophylaxis, the parasite is killed once 
it enters the erythrocytic stages of the lifecycle, stop-
ping the infection at a low level of parasitaemia before 
it becomes clinically significant. Inhibitors of beta-hae-
matin formation, such as chloroquine and mefloquine, 
and (plastid) ribosomal inhibitors, such as doxycycline, 
are suppressive chemoprophylactics, and must be given 
for at least 2 weeks after leaving a malaria-endemic area 
to clear any parasites that emerge from the liver after a 
person has left the endemic area. Currently, the pre-
dominant oral prophylactics used by travelers are (rarely) 
mefloquine, doxycycline and atovaquone–proguanil. 
These were initially developed as treatments for uncom-
plicated malaria [15, 16]. They were subsequently shown 
to have good protective efficacy when delivered at lower 
doses on a weekly basis, in the case of mefloquine, and a 
daily basis in the case of atovaquone–proguanil, respec-
tively [17, 18].
Protective vaccine strategies have focused on develop-
ing an immune response which blocks the initial infec-
tion, using the parasite antigen CSP-1 (circumsporozoite 
protein; [19]). Although a high level of protection has 
not currently been achieved with such vaccine candi-
date approaches, they have provided a proof of concept 
that antibodies can be generated that prevent the initial 
infection of the hepatocyte by sporozoites [20–23]. Effi-
cacious vaccines would hold tremendous promise for 
prophylaxis, but unlike many viral infections, malaria is 
not a disease where natural infection results in sterilizing 
immunity, indicating that the bar to the identification of a 
highly effective vaccination regimen for malaria remains 
very high.
Identifying new classes of anti-malarial chemoprotec-
tive molecules targeting either blood- or liver-stage has 
historically been limited by the lack of known molecu-
lar targets and of high-throughput screening methods. 
However, in the last 10 years there has been a dramatic 
increase in the deployment of high density, phenotypic, 
cell-based high-throughput screens of Plasmodium blood 
stages [24] and new chemotypes, which are active against 
the blood stages of Plasmodium infection, have been 
identified [25]. These families of molecules can then be 
tested for activity against other stages of the parasite life 
cycle including hepatic schizonts. Examples in the Medi-
cines for Malaria Venture (MMV) pipeline of compounds 
having both blood and liver stage activity [1] include: 
the DHODH (dihydroorotate dehydrogenase) inhibi-
tor DSM265 [26, 27], the PI-4 kinase inhibitor MMV048 
(MMV390048; [28]) and the EF2 (Elongation Factor 2) 
inhibitor DDD498 (DDD107498; [29]), now also known 
as M5717. These molecules have helped identify new 
molecular targets in liver schizonts. Other scaffolds such 
as KAF156 [30] have good activity against hepatic schiz-
onts. However, although the main mechanism of resist-
ance generation involves PfCARL, KAF156’s molecular 
site of action is still to be elucidated [31]. More recently, 
high-throughput screens of the hepatic schizont stages 
have been carried out for murine parasites [32], increas-
ing the possibility of the identification of compounds 
which are selectively active against hepatic schizonts. 
The immediate challenge is to develop high-throughput 
hepatic schizont stage assays using sporozoites from 
Plasmodium falciparum, and progress in this direction 
is being made. This is particularly important in order to 
confirm activity of compounds without asexual blood 
stage activity, and to avoid a focus on murine-malaria 
specific prophylaxis.
Work on injectable depot anti-malarials was a key part 
of the previous malaria eradication campaign with the 
development of 4-4′-diacetylaminosulphone (DADDS), 
a long-acting prodrug of the DHPS inhibitor dapsone, 
and cycloguanil pamoate (CI-501; [33, 34]). Clinical pro-
tection over 3–5  months was achieved in the published 
clinical trial, but the dose had to be delivered deep into 
the gluteal muscle tissues (350 mg in adults) and caused 
local discomfort and abscesses [35]. Failure to protect 
was assumed to be due to cross resistance with pyrimeth-
amine, which was emerging at the time. Interest in long-
lasting anti-malarials was renewed in 1976, supported 
by the UNDP/World Bank/WHO special program for 
Research and Training in Tropical Disease [WHO CHE-
MAL/SC(33)77.3 item 1.2] and the US Army Medical 
Research and Development Command. These groups 
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continued to focus on blood schizonticides for injection, 
but no molecules were brought forward for testing in 
field studies. Tafenoquine/WR 238605, an 8-aminoquino-
line originally discovered by The Walter Reed Army Insti-
tute for Medical Research has recently been approved by 
the US FDA (Food and Drug Administration) as a weekly 
oral prophylactic against Plasmodium vivax and P. falci-
parum  (Arakoda®, 60 Degrees Pharmaceuticals) and for 
a single-dose radical cure indication (i.e. the treatment of 
the liver stage, preventing P. vivax relapse), as  Krintafel®, 
by GSK. Both uses require a test for a patient’s G6PD 
(glucose-6-phosphate dehydrogenase) deficiency status 
as a safety measure. No further clinical work on injecta-
bles has been reported. In the 1980s, Chinese scientists 
investigated the use of pyronaridine given by injection, 
with a total intramuscular dose of 300–400  mg being 
given in two or three injections. The drug was rapidly 
absorbed and provided an efficacious concentration that 
remained for an extended period given the elimination 
half-life of 60 h [36].
More recently, there has been a significant effort to 
develop anti-virals that provide protection against HIV 
infection in high risk individuals using daily oral dosing, 
termed pre-exposure prophylaxis, PrEP [37]. However, 
clinical trials have shown variable rates of efficacy with 
low rates of protection, correlated with non-adherence to 
the daily oral drug regimen [38]. Long-acting injectables 
have been developed based on the reverse transcriptase 
inhibitor cabotegravir (GSK1265744) and the integrase 
inhibitor rilpivirine. These provide an opportunity for 
better adherence through protection when administered 
on a monthly or even less frequent basis [39]. Similar 
issues have been addressed in the realm of anti-psychotic 
medicines, where non-adherence to daily oral regimens is 
also a challenge [39].
When considering new molecules that could be used 
in chemoprotection, it is important to consider their 
ultimate use, since this drives the regulatory strategy. 
As mentioned earlier, previous generations of medi-
cines, such as mefloquine and atovaquone–proguanil, 
were first approved for case management, and were 
only subsequently approved for use at lower doses for 
prophylaxis. However, if the priority is to deliver new 
medicines for prophylaxis rapidly, one alternative 
approach would be to pursue a path towards initial reg-
istration directly for prophylaxis; this would require a 
new clinical and regulatory approach. The key ques-
tion is to define how large and diverse a population will 
need to be exposed to a new medicine before the risk–
benefit balance is established and considered adequate, 
and this ratio is clearly different between a medicine 
used for treatment and one for prophylaxis. Another 
question relevant to development is how to protect the 
new drug; any deployment strategy must also take into 
consideration the need to protect the drug against the 
emergence of resistance [40]. The assumption made 
here is that a combination of two molecules with differ-
ent mode of action would be ideal to protect against the 
selection of resistance. It is conceivable to use a single 
molecule, if the case could be made that the potential 
development and transmission of resistance in human 
subjects would be minimal [41]. Such a case would be 
strengthened by targeting non-replicating or low-copy 
number stages, such as the sporozoite. The key factor 
in reducing the risk of resistance generation is avoid-
ing exposure of the drug in subjects with existing 
parasitaemia. At first glance the ideal medicine would 
prevent development of the blood-stage of the infec-
tion, by killing all parasites before they escaped from 
the liver. However, a subclinical blood-stage infection 
may also drive some protective immunity, and so could 
even be advantageous, as long as the prophylactic drug 
achieved clearance of the blood stage infection.
Previously, targets have been proposed for the char-
acteristics of molecules which could be used as oral 
medicines in prophylaxis, and a target candidate profile 
for molecules with hepatic stage activity (TCP-4); [42]). 
It seemed timely, therefore, to revisit the characteristics 
of an injectable therapy for prophylaxis for a number 
of reasons. First, over the last 2 years there has been an 
increasing interest in the potential for long-acting inject-
ables, perhaps driven by the success in the antiretrovi-
ral arena, and also the re-assessment of the difficulty of 
obtaining a vaccine with high efficacy and a long dura-
tion of protection. Second, there has been a renewed 
interest in the use of monoclonal antibodies to protect 
against the establishment of a liver stage infection. This 
is largely driven by the availability of monoclonal anti-
bodies against the Circumsporozoite Antigen-1 (CSP-1), 
coming from the recent RTS,S clinical trials. Third, there 
has been dramatic progress in protecting children from 
infection in the Sahel by Seasonal Malaria Chemopreven-
tion (SMC) since the new strategy was recommended by 
the WHO in 2012 [43]. Here, administration of full treat-
ment courses of 3 days of amodiaquine and one dose of 
sulfadoxine–pyrimethamine were delivered to 15 mil-
lion children in 12 countries in 2016 [44]. This raises the 
question as to whether such chemoprevention could be 
replaced by a more easily delivered chemoprotection regi-
men (chemoprevention is use of a full treatment course 
for prophylaxis, chemoprotection is using a specifically-
designed and tested prophylaxis regimen). A once-per-
season injectable regimen would certainly be worth 
considering. Moving to chemoprotection (prophylaxis), 
rather than simply using a full treatment course monthly, 
requires a new regulatory and clinical approach, and 
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early discussions on this strategy have taken place with 
regulators during the past 2 years.
In a discussion of potential new medicines there are 
always many moving parts. A common framework for 
discussion and agreement on the ideal and minimally 
acceptable protective efficacy and other qualities of new 
medicines is important, given the lengthy development 
required from discovery to launch. In the world of inject-
able chemoprophylaxis, such a discussion is especially 
important, given the overlap between the potential uses 
for injectable small molecules, therapeutic antibodies, 
and vaccines. Based on these insights, the Target Can-
didate and Product Profiles (TPPs) presented here will 
need to be refined and updated in discussions within 
the malaria community, as and when new data become 
available.
The different modalities for deploying malaria 
prophylaxis
There are multiple uses for an injectable anti-malarial 
prophylaxis (Table 1). The first is to protect populations 
such as migrant workers, soldiers, tourists and university 
or boarding school students originating from a malaria-
free area from becoming infected when they travel to 
areas with endemic malaria. Historically prophylaxis has 
been considered as a premium priced market, largely tar-
geting western tourists and the military, who can afford 
to pay $5/day for protection. However, as the impact of 
malaria elimination has progressed, there are now many 
areas, especially in Africa, where it is relatively easy to 
travel from a low endemic to a high endemic region, such 
as from Southern to Northern Zambia. This latter group 
is an important and expanding group in the malaria 
agenda. With the progress of the elimination agenda 
there will be a need for affordably-priced protection for 
Africans who move from low to high transmission areas. 
Another important group is residents of non-endemic 
areas, such as Europe or the USA, whose families come 
from an endemic area and who return to visit their fami-
lies in a malaria endemic area. This group is responsible 
for the highest proportion of cases of imported malaria 
in Europe.
The second use is to protect a non-immune popula-
tion within their area of residence, who are suddenly 
exposed to a malaria outbreak or epidemic. This is one 
of the major concerns late in any eradication effort, in 
places where ‘maintaining zero’ is the priority [45]. In a 
situation where areas are malaria-free, but the mosquito 
population is still abundant, there may be a need to rap-
idly protect populations. In such situations both adults 
and children will need to be protected. It may not be pos-
sible to test the population for pregnancy status, so the 
ultimate challenge here is to have a medicine which has 
a high probability of being safe in the first trimester of 
pregnancy. A variant on this is the protection of popula-
tions from malaria during a pandemic outbreak of febrile 
disease, such as Ebola. During the 2013–2016 outbreak 
of Ebola in West Africa, many patients who presented 
with malarial fevers were triaged into the Ebola facili-
ties, where they became infected with Ebola [46–48], 
resulting in patients not seeking malaria treatment and 
an increase in deaths due to malaria [49]. Monthly pre-
sumptive treatment with artemisinin-based combination 
therapy (ACT) was used in at-risk populations in Liberia 
and Sierra Leone. An injectable prophylaxis could be use-
ful in this kind of situation, if it gave a longer period of 
protection than oral medication.
The third potential use for an anti-malarial chemo-
protective agent is to protect vulnerable populations 
in areas of high malaria incidence, and this is some-
what distinct from the other uses. Over recent years, 
there has been a massive deployment of sulfadoxine–
pyrimethamine plus amodiaquine (SP–AQ) for SMC. 
Chemoprevention is defined as giving a full curative 
course of treatment. This is given over 3 days, to each 
child under 5 years old, monthly throughout the rainy 
season in the Sahel (to 13 million children in 2016), to 
reduce the incidence of symptomatic malaria in this 
vulnerable population. Since a large part of the cost 
of deployment of SMC is the delivery, a better treat-
ment would be a once-monthly, single oral medication. 
A longer-acting injectable would have to offer signifi-
cant advantage, which is why the ideal threshold for 
this use has been set at 3 months in the target product 
profile shown in Table  2. The nuance here is that the 
clinical development strategy of the injectable would be 
for protection, as discussed below, rather than using a 
standard treatment dose and, therefore, in theory the 
dose would be better titrated to the needs of protection.
The regulatory strategy in each case would be to file for 
an indication of ‘Prophylaxis against Plasmodium falci-
parum malaria’. This would be defined as prevention of 
malaria infection in subjects travelling from geographi-
cal areas with no, or very low risk of malaria infection, to 
geographical areas with significant risk of malaria infec-
tion. The clinical development strategy supports the filing 
by collecting data to demonstrating acceptable efficacy, 
safety and tolerability in the target populations.
Defining a product profile for injectable 
prophylaxis
The discussion of a TPP for an injectable prophylactic 
medicine is informed by the uses described above. The 
final acceptance of an injectable product is guided by 
experience with two other therapeutic or preventative 
approaches. First, site injection tolerability, in terms of 
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needle size, and injection volume should be driven by a 
favourable comparison to vaccines. The most advanced 
malaria vaccine,  Mosquirix® (RTS,S–AS202) has been 
approved by the European Commission after having 
been given a positive scientific opinion by the CHMP 
(Committee for Medicinal Products for Human Use at 
the EMA (European Medicines Agency), and is about to 
undergo Phase IV in-country studies. The current course 
of vaccination involves four 0.5 mL intramuscular injec-
tions with a 25-gauge needle, at a cost of around $5 per 
injection in infants. Second, in HIV infections, where 
an effective vaccine has also been a major challenge, 
pre-exposure prophylaxis, or PrEP, using an injectable is 
being studied [37, 50]. Although large injection volumes 
and needle have been found acceptable, for example, in 
the injection of penicillin-G benzoate crystals for bacte-
rial infections, such as mass treatment against yaws [51], 
a new medicine for children protecting against malaria 
would need to be more child-friendly to be acceptable 
for repeat use. Intravenous injection of the PfSPZ vac-
cine [52] with a very fine needle has been very well toler-
ated even in very small children, but i.v. injection would 
probably not be the ideal route to achieve a prolonged 
duration of protection. From a formulation and phar-
maceutical perspective, intramuscular or subcutaneous 
depot approaches are preferred to achieve the desired 
long duration with new chemical entities.
The level of efficacy required for a new product can be 
gauged by the efficacy of current prophylaxis. In com-
parative, randomized clinical trials, nonimmune adults, 
adolescents and children (≥ 11  kg) visiting malaria-
endemic regions and receiving once-daily atovaquone/
proguanil (250/100  mg in adults and dosage based on 
body weight in children < 40  kg), had no cases of falci-
parum malaria for 28 days [53], comparable efficacy was 
also seen in other studies [54, 55]. Doxycycline provides 
84–99% protection (studies cited in [41]). Lessons from 
the vaccine community also suggest that a protective 
Table 2 TPP for an injectable prophylactic medicine for malaria
PK pharmacokinetic, (S)AE (severe) adverse event, ICH International Conference on Harmonization
Parameter to be clinically evaluated 
for the combination
Minimum essential Ideal
Antimalarial effects Blood schizonticides with at least one molecule 
also having causal prophylactic activity (killing 
hepatic schizonts)
Both molecules should have causal prophylactic, 
blood schizonticidal and transmission-blocking 
activities
Mechanism of action Two partner drugs without cross resistance Two partner drugs have different modes of action, 
so no cross resistance
Dosing regimen Once per month, intramuscular, with an accept-
able injection volume
Once per 3 months, intramuscular or sub-cutane-
ous with an acceptable injection volume
Rate of onset of action Protection, within 72 h of initial injection Immediate protection (no lag prior to onset of 
action)
Clinical efficacy ≥ 80% protective efficacy ≥ 95% protective efficacy: reduction in incidence 
of symptomatic malaria
No drug-resistant parasites identified in volunteer 
infection studies still capable of transmission
Drug–drug interactions No unmanageable risk in terms of solid state or 
PK interactions
No risks in terms of solid state or PK interactions 
with other co-administered PrEP or therapeutics
Safety and tolerability No drug-related SAEs; minimal drug-related 
AEs—i.e., not resulting in clinical study 
exclusion. No unacceptable pain, irritability 
of inflammation at injection site, especially 
injection abscesses
Idem
Use in patients with reduced G6PD activity Testing not required as no enhanced risk in 
mild-moderate G6PD deficiency
Testing not required as drugs not linked to 
haemolytic risk
Use in infants/children Use in children > 6 months old Use in infants, children and adults
Formulations Suitable for intramuscular injection with minimal 
preparation; maximum volume of 2 mL for 
adults and 0.5 mL for infants, administered 
with 27 gauge needle; partner drugs can be 
injected separately
Liquid pre-filled injection device for intramus-
cular; maximum volume of 1 mL for adults 
and < 0.5 mL infants administered with 27–30 
gauge needle; fixed dose combination of the 
drugs; or subcutaneous injection if volumes 
smaller than above for intramuscular injection
Cost of treatment < 5 USD per injection ≤ USD 1 for infants, USD 2 for children, USD 4 for 
adults
Shelf life of formulated product (ICH guidelines 
for zones/IVb)
≥ 2 years ≥ 3 years
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efficacy of ≥ 80% for a once per 3-month injection might 
be acceptable. The current working hypothesis is that a 
molecule either preventing or treating hepatocyte stage 
infection would be useful when looking at new chemical 
entities. However, molecules with pure blood stage activ-
ity (chloroquine and mefloquine) have been the mainstay 
of oral prophylaxis and so whether this would be accept-
able for an injectable remains a question for further 
discussion.
The clinical safety requirements of a long-acting inject-
able for prophylaxis are much more difficult to define 
precisely in advance of data. The two overriding princi-
ples are that first, the drug will be given to subjects with 
no overt disease, and so the safety thresholds should in 
general be similar to those required for vaccines. This 
will inevitably lead to the need for considerable phase IV 
activities. The second aspect relates to the long plasma 
residence time of pharmacologically active material. 
Appropriate safeguards have to be in place for the care of 
subjects, should a severe adverse event occur, and clearly 
such an event would preclude further development of the 
medicine for populations in low-resource settings. How-
ever, it is important to underline the fact that the safety 
considerations related to an injectable drug driving expo-
sure over several months are very similar to the safety 
considerations related to an oral drug driving exposure 
over several months. The ideal medicine is one that can 
be used to protect all ages; however the development of 
the medicine for children will require particular care, and 
the availability of substantial safety data in adults before 
proceeding to the more vulnerable younger populations.
A target product profile (TPP) including other param-
eters for an injectable prophylactic medicine for malaria 
is proposed in Table 2.
Approaches to finding and developing new small 
molecule TCP‑4 candidates
Compounds with a TCP-4 profile would normally be 
shown to be highly potent against the hepatic schizonts 
of P. falciparum parasites. The definition of a hit and a 
lead still follow the criteria discussed previously [56], 
with compounds showing an  IC50 of less than 1 µM being 
considered as potential starting points for medicinal 
chemistry, aiming for a final potency of less than 10 nM. 
The key data however are those that increase our under-
standing of how well this translates into in vivo efficacy, 
and allowing an early prediction of the human effective 
dose.
In vivo measurements of efficacy have been per-
formed traditionally using infection with GFP- (green 
fluorescent protein) or luciferase-expressing Plasmo-
dium berghei sporozoites in mice. This assumes equi-
potent activity between P. berghei and P. falciparum. A 
newer model is the FRG huHep chimeric mouse model 
with engrafted human hepatocytes and erythrocytes. 
FRG stands for the lack of functional Fah, Rag-2 and 
Interleukin 2 receptor common gamma chain genes in 
these animals. This model allows an endpoint based on 
asexual blood stage infection from the liver [57]. Here, 
the benchmarking with atovaquone shows that a highly 
efficacious compound should be able to lower the para-
site 18S RNA signal in the liver by  107-fold, or a 200-fold 
reduction in the bioluminescence signal [58]. DSM265, 
a novel PfDHODH inhibitor, with demonstrated activ-
ity in humans, shows a  104-fold reduction in this model, 
arguably defining the lower threshold of efficacy. During 
lead optimization, it is important to be able to assess the 
human effective dose, i.e. the dose required to produce a 
similarly effective exposure in humans. In the absence of 
imaging technologies to determine the time-dependent 
concentration of a drug within the liver, the definition 
of the prophylactic concentration has to be based on 
the plasma concentration, assuming that the plasma to 
hepatocyte concentration ratio is invariant with plasma 
exposure. The minimum protective plasma concentra-
tion in the mouse model can then be used as the basis for 
pharmacokinetic modelling of the human exposures. For 
a pre-clinical orally active compound the ideal threshold 
is an adult dose of < 100  mg, or < 2  mg/kg. Similar con-
straints apply to injectables, but driven by a need to be 
able to deliver the drugs in an acceptable injection vol-
ume of < 0.5 mg per drug, as discussed below. Two other 
biological factors are important. First, the demonstration 
that clinical selection of mutations is a rare event, or that 
these mutations are not transmitted. It has been shown 
that is relatively easy to select for mutations against 
atovaquone both in vitro and in patients, but that these 
mutations are difficult to transmit [59]. Second, species 
selectivity: although 99% of the global burden of disease 
is currently carried by P. falciparum, activity against 
other species would be an advantage, since many patients 
have mixed infections that include P. vivax, Plasmodium 
malariae and Plasmodium ovale.
Selection of a formulation, which may also involve the 
use of pro-drugs, is critical to enable the maintenance 
of long-lasting protection. The ideal use case would be 
a 3-month coverage from a single injection, allowing 
potential protection for a season in some countries. Thus, 
compounds having high potency and very low clearance, 
and with formulations delivering long-term drug release 
into the systemic circulation are favoured. When con-
sidering the product presentation, a number of factors 
need to be taken into account, including but not lim-
ited to: cost of goods, a therapeutic product that can be 
stored at room temperature in climate zones III and IV, 
a formulation with a potential for local production, and 
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a formulation that is easy to administer. As such there is 
no published decision tree that maps the technology path 
for selecting long-acting injectable formulations. A range 
of different formulation technologies have been applied 
in commercial products, such as oil solutions, aqueous 
micro- and nanosuspensions, in  situ forming gels, and 
micro-particular systems. There is, hence, a good indus-
trial basis to define the most likely options that would ful-
fil both the technological elements as well as the cost of 
the product. In resource-limited settings, the first line of 
formulation will most likely be an oil solution or suspen-
sion of the micro- or nano-particulate drug, due to the 
simplicity of development and production of the formu-
lation, low cost of excipients and potential for thermal 
sterilization, which would allow local production. The 
use of an oil-based solution or suspension requires clini-
cally acceptable oils, such as fractionated coconut, castor, 
corn, cottonseed or olive oils. A key consideration here 
will be local tolerability [60].
The second option for a long-acting injectable for pro-
phylactic treatment of malaria would probably be an 
aqueous suspension of either micro- or nanoparticles. 
The advantage of an aqueous suspension is that there is 
a well-established relationship between particle size and 
rate of dissolution. This allows much better control of the 
rate of release of the drug and, therefore, better match-
ing of the final pharmacokinetics, once the human clear-
ance is known. In the case of oil solutions of the drug, the 
oil is metabolized by macrophages in the muscle over a 
period of days to weeks, resulting in an amorphous depot 
of drug in the tissue. Data from preclinical animal models 
and in humans have demonstrated that appropriate slow 
release of a drug can be obtained, although the choice of 
oil is largely empirical at this stage. The technology asso-
ciated with aqueous suspensions is well established, i.e. 
production facilities and capacity are available, however, 
cost of goods is a bit higher than the oil solutions, and the 
development complexity the same.
Selection of compounds for long-acting injectable for-
mulations have historically been an afterthought, so the 
physico-chemical properties needed for success have not 
been well mapped. The selection criteria depend on the 
final technology; for an oil based solution, a crystalline 
material with high solubility (> 75 mg/mL in triglycerides, 
low aqueous solubility at pH 7.4 < 10 µM, high lipophilic-
ity (ideally logD > 4) and high melting point of the free 
form (> 150 °C) are favoured. Ironically, these are proper-
ties usually avoided by medicinal chemists when develop-
ing an oral product. The definition of the range for logD is 
under discussion as recent investigations have shown that 
there is limited correlation between this parameter and 
the ability to formulate in a lipid based vehicle [61]. The 
choice of final presentation will be governed by solubility 
in oil, aqueous solubility at pH 7.4 and the stability of the 
formulation under forced-degradation conditions. The 
molecules for injection can be the parent molecules, or 
pro-drugs synthesized with increased lipophilicity and oil 
solubility to fit the parameters described above. However, 
pro-drugs bring the complexity of requiring the preclini-
cal safety and exposure to both the active molecule and 
the pro-drug to be determined. The stability of the drug 
product, especially as a pre-filled sterile solution is par-
ticularly critical to ensure adequate shelf-life in tropical 
conditions, as a cold chain requirement for an injectable 
TCP-4 prophylactic would not be ideal.
Ideally, the drug should be administered either sub-
cutaneously or intramuscularly. The former has the 
advantage that it is easier to administer, and requires less 
training, but there is a greater constraint on the volume 
that can be delivered. Given that the ultimate product 
will target the protection of children, infants and adults, 
the proposed final volume is 0.5 mL for infants and chil-
dren, and 2.0 mL for adults.
The needle size is provisionally suggested at 27-gauge, 
to minimize discomfort during the injection. Signifi-
cantly larger volumes of administration are routinely 
given, such as the 4 mL of microcrystalline penicillin-G 
benzoate through a 21-gauge needle [62], which is never-
theless very painful. However, the success of this product 
will ultimately depend on its acceptability by communi-
ties, and so conservative values have been taken. The 
needle size determines the maximum viscosity of the 
injected material, which may restrict the uses of certain 
oil-based vehicles for small molecules, or the maximum 
protein concentration in the case of an antibody.
Alternatives to injections are implant systems, as 
used in long-term contraception. These have the poten-
tial advantage of controllability, with the possibility of 
removal should an adverse event occur. But this approach 
requires potent molecules that allow limited dosage: con-
traceptive etonogestrel implants only contain 68  mg of 
drug [63]. Implants have not been developed for paedi-
atric use.
The safety of the molecules is of paramount impor-
tance, whether considering long-acting injectables or 
long-acting oral molecules. In the case of any safety 
concern, removal of an active drug from plasma would 
require extensive dialysis, if feasible for the molecule, and 
lack of access to such a procedure could be life-threaten-
ing in resource-poor settings. It is, therefore, important 
to consider potential long-acting injectables within three 
tiers of risk:
• The first tier would consist of molecules for which 
extensive human systemic safety data already exist. 
This would apply to new formulation or a prodrug 
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of a molecule already used for prophylaxis, such as 
atovaquone–proguanil. Here the safety and toler-
ability of the combination is well understood for oral 
administrations of up to 60  days, enabling an ade-
quate assessment of the risk–benefit balance, and giv-
ing a relatively straightforward, albeit cautious path 
to human studies. In the initial single ascending dose 
studies in humans, the increase in dose should pro-
duce an increase in  Cmax and an increase in the dura-
tion of significant plasma concentration. As such, the 
initial first-in-human study can be de-risked by the 
selection of an appropriately low starting dose (this 
group of candidate molecules could also include new 
monoclonal antibodies, provided that they could be 
shown to be free of cross-reaction with any host tar-
gets and lack target-based enhancement of infectivity 
or inappropriate immune activation).
• The second tier would be prodrugs of new chemical 
entities with oral formulation for which initial human 
safety data can be collected using the oral route, 
allowing dosing to be halted in case of adverse events 
of concern. Testing of parenteral formulations could 
follow, but there would be no understanding of rare 
serious adverse events until after Phase III trials.
• The third and most difficult tier would be molecules 
for which no oral formulation of the active parent 
is possible due the physico-chemical properties of 
the agent. Given the required long plasma residence 
time, the starting dose in initial clinical trials would 
have to be extremely low, and the dose escalation 
between cohorts extremely conservative.
In some of the uses described above, the population at 
risk from malaria will include a considerable number of 
women of childbearing potential, whose pregnancy sta-
tus may not be determined. For new molecules coming 
forward for prophylaxis, early analysis of the develop-
mental and reproductive toxicology (DART) would be 
an essential part of the development strategy. Absence 
of any signals in such preclinical studies would facilitate 
the inclusion of women of childbearing age in clinical 
studies. This could facilitate early use of such an agent 
in the larger population. As discussed below, monoclo-
nal antibodies offer a considerable advantage, since the 
materno–fetal transfer of IgG during the first trimester is 
minimal [64, 65].
The preclinical candidate will be a single molecule. 
There is still debate within the community as to whether 
the final product should be a single molecule or a com-
bination. The potential for the selection of resistance 
is much lower than when a molecule is used for the 
treatment of uncomplicated malaria, since the mol-
ecule encounters far fewer parasites [66]. However, 
asymptomatic infections with quite high parasitaemias 
of > 5000/µL are frequently observed, and it is possible 
that there are pre-existing mutations within the sporo-
zoite population, emphasizing the need for caution [67]. 
Resistance generation against antibodies is not expected 
to be a significant problem, provided that the antibod-
ies are generated against conserved non-variant antigens 
from non-dividing forms, such as sporozoites, unless of 
course, pre-existing mutations are prevalent.
In this review a conservative approach of taking two 
active molecules has been adopted. This is important 
in early development discussions, as early human vol-
unteer studies require the availability of formulations 
for both molecules that are compatible. The additional 
twist in this compatibility discussion is that the drug 
exposure profile of each molecule in the blood needs to 
be compatible and since this is modulated by the kinet-
ics of release from the initial depot it may be difficult to 
do this for two individual molecules with different phys-
icochemical properties. Matching pharmacokinetics is 
important both for duration of efficacy and for mitigating 
the risk of emergence of resistance during the extended 
tail of exposure. In theory, separate injections of the two 
drugs is possible, although this would be a large disad-
vantage. Seriously mismatched pharmacokinetics would 
limit the use to applications where subjects are outside of 
high transmission zones during the tail exposure period; 
again, this is possible, but not ideal. As such, any preclini-
cal safety and toxicology studies may have to be repeated 
with the final formulation.
Initial proof of concept in man can be performed in 
volunteer infection studies with sporozoites. Recent 
studies with oral small molecule inhibitors of parasite 
liver stages have demonstrated clinically useful activity 
with relatively small cohorts, either using direct injec-
tions of sporozoites or insect-delivered sporozoites [26, 
27]. For small molecules targeting hepatic schizonts, both 
approaches give similar results, with the direct injection 
of sporozoites being operationally easier. For antibody 
therapeutics targeting sporozoite antigens prior to infec-
tion of the liver, there is still a need to confirm the best 
approach.
The TCP-4, for a single molecule suitable for develop-
ment as part of a new injectable, combination regimen 
for prophylaxis against malaria is detailed in Table 3.
Monoclonal antibodies for long‑acting malaria 
prophylaxis
An alternative approach to protecting vulnerable popu-
lations with an injectable small molecule would be the 
use of a monoclonal antibody [68]. Even though malaria 
infection in humans does not lead to a sterilizing immune 
response, it is still possible that monoclonal antibodies 
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with sufficient affinity and prolonged plasma residence 
times could provide protection from infection [68]. The 
exquisite selectivity of monoclonal antibodies means 
there should be no interaction with host targets, and the 
off-target safety issues can be avoided. Most published 
work is on antibodies that prevent sporozoite invasion 
of hepatocytes or merozoites infection of erythrocytes. 
These antibodies could be compared with small mol-
ecules for TCP-4 (hepatic schizonts) or TCP-1 (eryth-
rocytic schizonts) with the subtlety that the antibodies 
prevent the initial infection of the respective cell types, 
whereas small molecules prevent the replication of the 
parasite within the host cells. In both cases the time win-
dow for action of an antibody is a critical element which 
distinguishes the antibody profile from the drug profile. 
An antibody against sporozoites must be able to act in 
the short time that it takes for sporozoites to move from 
the skin to the liver, typically within 30 min. Antibodies 
against merozoites must exert their effect in the short 
window when the merozoites are present in free circula-
tion, typically 30 s.
Given the high commercial price of many existing 
antibody therapies, it is often assumed that the cost of 
antibody therapy would be prohibitive in most malaria-
endemic countries. Provided antibodies are expressed 
at high levels (4  g/L), and are stable, hence the produc-
tion costs can drop from around $100–300/g [69] to esti-
mates of around $35–85/g [70], with room for a further 
decrease in costs, projected to be $20/g at the multi-
tonne scale.
As with small molecules, an intramuscular or sub-cuta-
neous presentation is probably preferable to intravenous 
injection, and so a limiting factor is the volume of admin-
istration. The amount of antibody is, therefore, limited by 
the achievable concentration. Although concentrations 
as high as 200  mg/mL have been reported for subcuta-
neous injection, a more conservative target is 100  mg/
mL [71]. Based on a 0.5 mL injection volume for children 
and 2 mL for adults, this sets a dose ceiling of 50 mg and 
200 mg, respectively (Table 2). This in turn sets an opti-
mized cost maximum for the antibody at $1.75 for chil-
dren and $7 for adults, excluding the costs of vials and 
distribution. These price estimations are on the border-
line of what might be acceptable, in comparison with the 
pricing for a malaria vaccine. Any decrease in dose, fre-
quency of administration or cost of manufacturing would 
further bring down these costs.
To achieve long-term prophylaxis, mutations in the 
Fc region are needed. Monoclonal antibodies tend to be 
IgGs, with plasma half-lives of 20–25 days [72, 73]. This 
half-life is partly controlled by FcRn receptor-mediated 
elimination, and also depends on the antigen abundance. 
Mutating the IgG Fc region to increase the interaction 
with its receptor FcRn, at the acidic pH encountered in 
the lysosome, prevents elimination of the antibody in the 
lysosome, favouring its recycling. This can extend the cir-
culation duration of an antibody threefold, as has been 
achieved for bevacizumab and cetuximab [74], through 
simple Met428Leu and Asn434Ser mutations. Other 
approaches to half-life extension make the antibody bulk-
ier by fusion, mulitmerization or pegylation, but these 
approaches would dramatically increase the cost of goods 
[75].
An antibody could be compared directly with a small 
molecule in the animal model. The goal would be an 80% 
protection from infection, minimally for 1  month and 
ideally for 3 months. Given the restrictions on injection 
volume, this would require administration of 2 mg/kg of 
each active molecule in adults and 2–5 mg/kg in children. 
As for small molecules, the simplest preclinical model 
for therapeutic antibodies would be the FRG chimeric 
mouse model with engrafted human hepatocytes, dis-
cussed earlier. Allometric scaling for a series of antibod-
ies [76] suggests that systemic clearance is proportional 
to the body weight raised to a power of 0.91 (Cl = a·BWb), 
a much higher number than seen with small molecules. 
Therefore, allowing for the difference in body weights 
for humans and mice, this translates approximately into 
a twofold difference in the mg/kg dose between humans 
and mice, setting an efficacy threshold in mice of an 
80–200 mg total dose. This could be related back to a cel-
lular potency target  EC50 < 100  pM (< 15  ng/mL), based 
on modelling of various affinity and dissociation rates 
[77, 78]. It is important to demonstrate in such studies, 
that there is no risk of stimulating antibody-dependent 
enhancement [79].
As mentioned above, the exquisite selectivity of anti-
bodies means that off-target effects are minimized. Anti-
sporozoite or anti-merozoite antibodies do not target 
host antigens. Therefore, toxicology studies should be 
less complicated compared to other indications. Fetal 
transfer in the first trimester is reported to be minimal; 
the required Fc receptor for the transfer of IgGs is hardly 
detectable in the placental syncytiotrophoblast during 
the first trimester [80]. Specific studies on monoclonal 
antibodies in pregnancy are rare, given that most anti-
bodies are given for treatment of cancer or autoimmune 
diseases. Several studies have reported that multiple scle-
rosis patients in early stages of pregnancy exposed to 
natalizumab or alemtuzumab did not have an increase in 
the frequency of abortions [81]. In Inflammatory Bowel 
Disease, the European evidence-based consensus is to 
continue treatment with anti-TNF throughout preg-
nancy, and the practice appears safe [82]. This means that 
antibody prophylaxis could potentially be given to young 
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women whose pregnancy status is unknown, which is a 
tremendous advantage over new chemical entities [64].
Antibody discovery tends to be much faster than for 
small molecules, with a much higher probability that an 
individual project will deliver a development candidate 
[83]. However, once a development candidate is defined, 
the production of high-grade material for the initial 
clinical trials is much more expensive. Typical costs are 
in the region of $5 million, which contrasts starkly with 
around $100  k for a small molecule. This combination 
of an easier pathway to candidate identification, but a 
more expensive decision stage gate, means that it is very 
important to have clear parameters for the TCP.
Clinical and regulatory strategy of long‑acting 
malaria prophylaxis
For new chemical entities and antibodies the Phase I sin-
gle ascending dose study in healthy volunteers would aim 
to achieve the plasma concentration predicted from stud-
ies using the FRG-mice [84]. At this concentration, pro-
phylactic activity could be assessed in human volunteer 
malaria infection studies [26, 27]. For new chemical enti-
ties, the safety and efficacy in human volunteers should 
ideally be established initially using an oral formulation, 
which will help guide the safety recommendations for 
dose escalation of the injectable in Phase I.
In parallel, it is important to investigate the poten-
tial combinations of two molecules that can be brought 
forward. Simulations using data from preclinical 
cytochrome P450 and transporter assays can help elimi-
nate combinations with likely problematic drug–drug 
interactions. Additivity and possible synergy between 
two molecules can be studied in the FRG SCID mouse. 
Exposure–response analyses of these studies also allow 
modelling of the doses proposed for Phase II trials. In 
addition, the modelling has the potential to demonstrate 
the contribution of the individual compounds to overall 
efficacy, addressing the ‘combination rule’ required by the 
US FDA. The safety of combinations needs to be inves-
tigated in healthy adult volunteers combination studies 
before moving to Phase II trials in infected but asympto-
matic subjects. A flow chart for the selection and optimi-
zation of new molecules with potential chemoprotective 
activity is shown in Fig. 1.
The Phase II and Phase III clinical strategy is based 
on the lessons learned from the development of 
atovaquone–proguanil [55, 85, 86] for malaria prophy-
laxis. Atovaquone–proguanil was first developed as a 
malaria treatment, and was subsequently shown to be 
efficacious in prophylaxis, using a daily dosing regimen. 
However, in the case of a new injectable protective regi-
men, the goal is to try to achieve registration for a proph-
ylaxis indication directly. Such a development plan for 
Fig. 1 Proposed high level clinical development plan for evaluation of a long acting malaria prophylactic
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prophylaxis was presented for initial discussion with reg-
ulators (the UK Medicines and Healthcare products Reg-
ulatory Agency, MHRA) in the context of an oral drug 
combination therapy. Similar considerations would apply 
for antibodies. Two main clinical trial designs are pro-
posed to support registration for a prophylaxis indication 
(Fig. 1). Phase II studies would be carried out in subjects 
resident within an endemic area, and Phase III studies 
would be undertaken in a genuine migrant population, 
such as seasonal workers, or boarding school children. 
Studies would be conducted in highly endemic areas, to 
obtain sufficient discriminatory power versus compara-
tor to demonstrate efficacy. Since it is thought that rela-
tively few children less than 5  years of age are likely to 
be travelling from malaria-free to malaria endemic areas, 
recruitment into clinical trials of this younger popula-
tion may be problematic. For this reason, the plan would 
be to seek approval for subjects over 5 years in the first 
instance. Recruitment of younger children is likely to be 
easier following approval of the medicine for prophylaxis 
in the older population, when sufficient evidence of safety 
and efficacy is available.
To support a stringent regulatory authority registra-
tion for prophylaxis, two Phase II studies are proposed 
in a non-naïve population (Fig.  1), the first carried out 
over 20 weeks in adults, and the second carried out over 
12 weeks in children of 5 years and above. Both studies 
would be randomized, double-blind placebo-controlled 
studies to evaluate the prophylactic efficacy, safety and 
tolerability in non-naïve subjects in regions of Africa with 
a high incidence of malaria. The primary endpoint would 
be protective efficacy (PE). A key aspect of this design is 
that a sterilizing cure is administered to study subjects to 
clear both blood-stage parasites and gametocytes prior 
to assessing the prophylactic efficacy of the drugs under 
investigation. This design is, therefore, a useful model 
of uninfected populations travelling to endemic areas, 
although the subjects will have the benefit of partial-
immunity from previous infections. From a study design 
perspective, this approach has the significant advantage 
of allowing the use of a placebo comparator, thus pro-
viding a direct measure of PE (defined as: 1-failure rate 
active treatment/failure rate of placebo).
In the first of these two studies, two to three combina-
tion dose levels or regimens could be evaluated, using an 
exposure–response approach in a relatively small number 
of subjects, to identify the optimal dose and frequency of 
dosing. Following the identification of the dosing regi-
men that provides the target protective efficacy with a 
practical dosing frequency, and with acceptable safety 
and tolerability, a small pharmacokinetic study or Phase 
II run-in could confirm that the dose adjustments in chil-
dren achieve the target drug exposures.
This would then be followed by a Phase II study in chil-
dren which would test the selected regimen in non-naïve 
school children resident in an endemic area. The design 
would involve a step-wise, age de-escalation approach. 
A full safety review would be carried out before enroll-
ing each new cohort, descending via cohorts of approx-
imately 30 10–16  year olds, to 5–10  year olds. The 
decision to move to Phase III would be based on the 
likelihood of achieving protection over 3  months. Such 
protection would ideally be in a population which had 
no protection supplied by immune memory. The dem-
onstration of activity only in a population with some 
background immunity could still be useful—for exam-
ple providing protection in pregnancy, or as a potential 
replacement for SMC. Since the effect of partial immu-
nity on the efficacy in the Phase II population cannot 
be estimated directly, a somewhat higher efficacy than 
required for Phase III could be set as the threshold to 
move from Phase II to Phase III. The acceptable efficacy 
for the prophylaxis indication will ultimately depend 
on the likely use cases and validation in further discus-
sion with the wider community, balancing efficacy and 
aspects such as deployment practicality, efficacy and cost 
per Disability Adjusted Life Year (DALY).
The use of a placebo in adults and children in the 
Phase II studies in areas of high malaria incidence was 
strongly recommended in initial discussions with regula-
tory authorities because this is the only circumstance in 
which the true attack rate is known, and hence the true 
protective efficacy can be measured. The population 
enrolled in this study would ordinarily be exposed to sub-
clinical malaria infection which would otherwise remain 
untreated. All subjects would receive an initial steriliz-
ing cure for this sub-clinical malaria, and benefit from 
close clinical safety monitoring during the study, as well 
as standard-of-care treatment upon detection of posi-
tive parasitaemia during study conduct. The acceptability 
of placebo controlled trials in adults and in children will 
need additional discussion with the Ethics Committees 
at individual sites, to take account of local concerns on 
this topic. There are sometimes ethical objections to pla-
cebo injections, especially if repeated blood sampling was 
undertaken. An alternative would be to combine the pla-
cebo or experimental drug with a proven vaccine against 
a different disease.
The protective efficacy, safety and tolerability would 
then be confirmed in a Phase III study in the target popu-
lation. These are adults and children older than 5  years 
travelling from geographical areas with no, or a very low 
risk of malaria infection, to geographical areas of sig-
nificant risk of malaria infection. Ethically, these studies 
need to be active controlled studies; oral atovaquone–
proguanil being the most likely comparator. The 
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protective efficacy of both atovaquone–proguanil and the 
NCE (new chemical entity) is expected to be high, there-
fore a very low rate of malaria infection (‘attack rate’) 
would be expected in this population, meaning that very 
large numbers of subjects would be required to demon-
strate non-inferiority of the new medicine. For this rea-
son, in the development of atovaquone–proguanil, the 
primary endpoint in Phase III studies was the overall 
frequency of any adverse events assessed at 7 days after 
leaving the endemic country, with protective efficacy as 
a secondary endpoint. In these comparator studies, con-
firmed P. falciparum malaria occurred in 0/486 and 0/477 
subjects receiving atovaquone–proguanil and meflo-
quine, respectively [55], and in 0/501 and 3/507 subjects 
receiving atovaquone–proguanil and chloroquine–pro-
guanil, respectively [87], illustrating the difficulty of this 
approach. Although atovaquone–proguanil is the best 
comparator, such studies have the additional complica-
tion of a lack of marketing authorization in many of the 
areas ultimately targeted.
Demonstrating non-inferiority of protective effi-
cacy would as mentioned above require very large tri-
als. Making a number of assumptions about the risk of 
developing malaria for travellers from Europe, Canada 
and South Africa to East Africa who do not take prophy-
laxis, the average duration of travel and the efficacy of a 
prophylactic treatment, Høgh et  al. [87] estimated that 
assuming a protective efficacy of chloroquine–progua-
nil of 72%, a study in travellers designed to show that a 
new anti-malarial drug with 95% efficacy is better than 
chloroquine–proguanil, assuming a 80% power and a 
5% significance level, would require more than 16,000 
participants While a number of the assumptions made 
would not necessarily apply to African migrants traveling 
for work and for schooling, perhaps for longer periods, 
and exposed to higher bite rates (due to greater ende-
micity, and a less protective living environment), nev-
ertheless unrealistically large numbers may be required 
to test for non-inferiority of efficacy. Indeed, given the 
reported 98.5–100% efficacy for atovaquone–proguanil, 
demonstration of non-inferiority would not be expected, 
but demonstration of high efficacy of the NCE would 
be required. Therefore, similarly to the development 
of atovaquone–proguanil, for a long-acting injectable 
prophylactic trial in adults proposed here (Fig.  1), the 
primary endpoint would be non-inferior safety and tol-
erability compared to atovaquone–proguanil, with pro-
phylactic efficacy as a secondary endpoint. Hence the 
required sample size of any future Phase III studies will 
be based on the most frequent and clinically relevant 
adverse event(s) of both test medicine and comparator, 
and the non-inferiority margin will be set based on a pro-
posed clinically relevant difference in adverse event rate.
In migrant populations a number of potential 
approaches have been published, including enrolment 
of subjects in Travel Clinics [55, 87], protection of sol-
diers on active duty, boarding school children or groups 
of workers deployed for short periods in hyper endemic 
regions [88].
In initial discussion with MHRA, a total safety popula-
tion of approximately 3000 subjects exposed to the clini-
cal dose was deemed a sufficient safety data package for 
registration of an oral prophylaxis, provided no signifi-
cant safety signals are detected. The breakdown numbers 
of adults versus children was not considered critical as 
long as there is a good spread of age across the study.
Conclusions
Several factors have driven a renewed evaluation of the 
role of prophylaxis in the malaria elimination agenda 
over the last few years:
• First, the general acceptance that countries that are 
undergoing elimination will have internal popula-
tions migrating from low transmission zones to 
those of high transmission, for example going from 
the south to the north of Zambia. In the past, the 
prophylaxis of migrant populations was considered 
only to be commercially relevant for protecting west-
ern tourists and soldiers. However, it is now clear 
that cost-effective solutions must be found to protect 
migratory populations in low- and middle-income 
countries.
• Second, in countries that have eliminated malaria 
and are ‘maintaining zero’ [12], there is the risk of 
re-introduction and epidemics, and in the absence 
of a fully effective vaccine, an alternative approach to 
protection is needed for populations at risk of an epi-
demic. A special subcategory is the need for malarial 
prophylaxis during fever outbreaks such as the Ebola 
crisis in West Africa, to reduce the risk of malaria at 
the height of the epidemic and to protect health care 
workers.
• Third, there have been tremendous successes in the 
last 5 years using SMC, which involves giving a full 
treatment course of anti-malarials every month. A 
regimen which was truly optimized for prophylaxis, 
and available as an injection would have potentially 
major benefit. This latter point has come into focus 
recently because of the stagnation in the reduction of 
malaria incidence globally [44]. One of the strategic 
responses here is to ask what else can now be done in 
high-burden countries to achieve significant reduc-
tions in morbidity, and new prophylaxis regimens 
that were simpler to administer than current SMC 
could have an even bigger impact and which could 
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potentially be given in areas with perennial high 
transmission.
Several factors lead to some optimism for the future:
• First is the availability of new chemotypes with activ-
ity against the malaria parasite, which opens up the 
possibility of focusing on new medicines specifically 
designed for prophylaxis. This is an appealing situa-
tion since, ideally, the same medicine should not be 
used for both the protection and the treatment of 
malaria within the same geographic locale. To date, 
none of the new molecules has a half-life equivalent 
to that seen from oral doses of 4-aminoquinolines or 
the 8-aminoquinoline tafenoquine, hence the need 
for slow-release injectable formulations, to provide 
the appropriate duration of cover.
• Second, the availability of better in  vitro P. falcipa-
rum liver stage assays and animal models, including 
a murine model of the hepatic infection of P. falci-
parum allows the comparison of different molecular 
classes in vivo. Standardization of protocols for such 
assays will be an important driving factor over the 
coming years, allowing head-to-head comparisons of 
small molecules and monoclonal antibodies.
• Third, in experimental medicine, the arrival of robust 
supplies of GMP-standardized sporozoites has ena-
bled testing of new chemical series in human vol-
unteer infection studies. These data, or alternatively 
those obtained in insect-driven infection studies, 
allow early identification of compounds with activity 
in humans, and estimation of human effective doses 
for full-scale clinical studies.
• Finally, new developments in formulation technolo-
gies allow the development of some of the molecules 
with prophylactic activity as long-acting injectables. 
This can be achieved by formulation of the parent 
compound or development and formulation of pro-
drugs. Developments in HIV, oral contraception and 
antipsychotic medicines have shown that slow release 
allowing protection for one or even several months is 
possible, with acceptable dosing volumes and needle 
sizes. These studies also underline the need for highly 
potent molecules, to minimize cost, and to maximize 
acceptability.
Taken together, there are many reasons to be optimistic 
about the probability of identifying and developing long-
acting injectable formulations. What is important is that 
a common language and common standards are applied 
to assess the different candidates, and on this basis Target 
Candidate Profiles are proposed. In addition, the route to 
registration will be a new one, not necessarily proceeding 
via the approval of medicines for a treatment indication. 
As such, new target product profiles and the use cases 
supporting their delivery in the field are important. This 
document contains proposals for such profiles, in the full 
knowledge that over the next few years clinical data will 
become available providing many lessons that aid in fur-
ther refinement of the next generation of profiles. More 
discussion is needed with experts in the field and the big-
ger malaria community e.g. on the clinically relevant level 
of efficacy to be targeted. Furthermore, MMV is prepar-
ing clinical development strategies for new prophylactic 
medicines and engaging stringent regulatory authorities 
in early discussions.
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